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Abstract: Acetyl-L-carnitine (ALC) has shown a neuroprotective effect in patients with
peripheral neuropathies of different etiologies. Preclinical studies demonstrated a central
anti-nociceptive action, both in neuropathic and nociceptive pain models. The present review
aims to provide the knowledge on the efficacy of ALC in patients with painful peripheral
neuropathy, based on the evidence. Consistent with the PRISMA statement, authors searched
PubMed, Embase and the Cochrane Database of Systematic Reviews for relevant papers,
including those issued before April 2018. Two authors independently selected studies for
inclusion and data extraction: only trials including patients with a diagnosis of peripheral
neuropathy and involving at least 10 patients were considered for the purposes of this review.
Fourteen clinical trials were revised, to provide the level of evidence for neuropathy. To
assess the global efficacy of ALC in painful peripheral neuropathy, a meta-analysis of four
randomized controlled trials was performed. Mean difference in pain reduction as measured
on a 10-cm VAS, and 95% CIs were used for pooling continuous data from each trial. Four
randomized controlled trials tested ALC in patients with neuropathy secondary to diabetes
and to antiretroviral therapy for HIV. Compared to placebo, ALC produced a significant pain
reduction equal to 20.2% (95% CI: 8.3%-32.1%, P<0.0001) with respect to baseline. Clinical
trials also showed beneficial effects on nerve conduction parameters and nerve fiber regen-
eration, with a good safety profile. These data indicate that ALC provides an effective and
safe treatment in patients with painful peripheral neuropathy. We recommend further studies
to assess the optimal dose and duration of the therapeutic effect (also after treatment
withdrawal).
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Introduction
An improved understanding of the pathophysiologic mechanism of neuropathic
pain has led to the use of previously unexplored therapies, with encouraging results:
among them, the acetyl-L-carnitine (ALC), ie the acetyl ester of L-carnitine pro-
duced by the human brain, liver and kidney, represents one of such recent ther-
apeutic approaches. This molecule is an acetyl-group donor and plays an important
role on mitochondrial energy homeostasis and detoxification1,2 Besides strengthen-
ing the actions of Nerve Growth Factor (NGF) actions,3–5 and promoting peripheral
nerve regeneration,6,7 ALC revealed a neuroprotective function in vitro,2,8 in vivo9
and in animal models of diabetic neuropathy.10 ALC has antiapoptotic effects in
peripheral mononeuropathy models,11 an antioxidant activity12 and accretes acet-
ylcholine production. Microdialysis studies have shown an increased acetylcholine
release in both rat striatum and hippocampus following ALC administration.13
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Due to its analgesic effect, ALC has gained a growing
clinical interest in different forms of chronic-pain neuro-
pathy, not only for treatment, but also for pain prevention.-
14,15 Several experimental models of neuropathic pain
documented the antinociceptive effect of ALC; such
model encompassed streptozotocin- and chemotherapy-
induced neuropathy, as well as the sciatic nerve chronic
constriction injury.6,16 Moreover, ALC provides a signifi-
cant antinociceptive effect even after the development of
neuropathic pain. These analgesic properties result from
different mechanisms. ALC is the only drug whose analge-
sic effect is due to an epigenetic mechanism, based on the
acetylation of p65/RelA, a transcription factor belonging
to the NFkB family. Acetylation of p65/RelA leads to a
strengthened expression of type-2 metabotropic glutamate
(mGlu2) receptors in the dorsal root ganglia and dorsal
horns of the spinal cord, thus reducing the glutamate
release from primary afferent sensory fibers.17,18 The
analgesic effect induced by ALC persisted for at least
14 days after drug interruption. A long-term analgesic
effect was also observed in mice after chronic constriction
injury of the sciatic nerve.17
The effect on pain of ALC is also modulated by nico-
tinic and muscarinic antagonists, as shown in a number of
animal studies, thus suggesting the role of the cholinergic
pathway in the antinociceptive activity of this drug.19,20
ALC may raise the uptake of acetyl-CoA into the mito-
chondria and, due to its similarity in structure to acetylcho-
line, it may also produce cholinomimetic effects.21
This systematic review and meta-analysis aim to pro-
vide the actual knowledge, based on the evidence, of ALC
efficacy compared to placebo in the treatment of neuro-
pathic pain in patients with peripheral neuropathy.
Materials and methods
Search process
We searched PubMed, Embase and the Cochrane Database
of Systematic Reviews for relevant papers, considering
publications issued before April 2018. The following
search terms were used: “acetyl-L-carnitine”, “neuropathic
pain”, and “neuropathy”. Full-length, original communica-
tions were included, limiting the search to English-lan-
guage publications. The review process was carried out
by two reviewers: only publications independently
approved by the two authors were taken into account
(Figure 1). The following inclusion criteria were consid-
ered: trials including patients with a diagnosis of neuro-
pathic pain related to peripheral neuropathy, and a
minimum sample size of 10 patients. A revision of the
selected clinical trials was carried out, to provide the level
of evidence, according to the guidelines for clinical prac-
tice recommendations of the American Academy of
Identification Records identified through database searching (n =123)
Title screening • Not relevant (n =10) 
• Experimental pain (n =52)
Abstract screening Abstracts assessed for eligibility (n =61)
Excluded (n =13)
Not relevant (n =4)
Full-text screening Relevant, full-text articles (n =44)
Clinical trials selected for the levels of evidence ( n =14)
RCTs included in the meta-analysis (n =4)
Included
•
•
Figure 1 Flowchart of the search process.
Abbreviation: RCTs, randomized controlled trial.
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Neurology (AAN).22 A meta-analysis of randomized con-
trol trials (RCTs), testing the effect of ALC in patients
with painful peripheral neuropathy was also performed.
For the purposes of the meta-analysis, we considered
only the RCTs with a homogeneous measure of the ALC
effect on pain, compared to placebo. The risk of bias of the
included RCTs was evaluated independently by two
reviewers, in accordance with the guidelines provided by
the Cochrane Handbook for Systematic Reviews of
Interventions 5.1.0.
Statistical analysis
We pooled the mean reduction of pain, compared to pla-
cebo, as measured on a 10-cm VAS. The pooled effect of
each study was described in terms of mean difference
(MD) with 95% CIs. Heterogeneity among studies was
assessed by analysing the relevant forest plots; the statis-
tical analysis consisted of a χ2 test of homogeneity and the
evaluation of the inconsistency index I2.23 An inconsis-
tency index I2>50% indicated a statistically significant
among-study heterogeneity: in this case, studies were
pooled using random-effects model. A subgroup analysis,
based on the cause of neuropathy (diabetes and antiretro-
viral toxic neuropathy), was carried out; heterogeneity
between groups was also evaluated. Forest plots of the
individual studies and the pooled average were also com-
puted, with the aid of GraphPad Prism 7.0.
Results
Clinical trials overview
Out of 44 full-text articles, the search process led to the
selection of fourteen clinical trials, whose characteristics
are summarized in Table 1. Such trials encompassed both
RCTs and open-label studies. To each of these studies we
assigned a classification level according to the AAN
method.22 Among them, only four RCTs were considered
for the meta-analysis.
Acetyl-L-carnitine in diabetic neuropathy
Three Class II RCTs compared ALC versus placebo in a
total of 1590 patients with diabetic peripheral neuropathy.-
24,25 The treatment efficacy on pain was evaluated using
a VAS.
Sima and colleagues carried out two RCTs with the
same design. ALC was administered at two doses (500 or
1,000 mg) three times a day (t.i.d.) for 1 year. Patients
treated with 1,000 mg ALC t.i.d. showed significant
improvements at both 26 and 52 weeks. Type 2 diabetes,
adequate drug compliance, and HbA1c >8.5% were asso-
ciated to the greatest benefit in pain reduction. Pain relief
was linked to improvements in clinical symptom scores
and morphometric parameters of sural nerve biopsy, ie the
increased fiber numbers and clusters of regenerating fibers.
No significant differences in nerve conduction study data
and in the incidence of adverse events between the two
groups of patients were observed.24
In the RCT of De Grandis and colleagues, 1,000 mg/
day of ALC were administered intramuscularly for
10 days; the dosage was then raised to 2,000 mg/day,
administered orally, until the end of the study (355 days).25
After 12 months of treatment, a significant reduction in the
mean VAS scores for pain was observed in patients treated
with ALC, compared with the placebo group. A significant
improvement in nerve conduction study parameters was
also found in treated patients. No serious adverse events
were reported.
A multicenter, double-blind RCT assessed the efficacy
and safety of ALC in diabetic peripheral neuropathy com-
pared with methylcobalamin.26 The study encompassed
232 patients, randomized to receive oral ALC 500 mg t.i.
d. or methylcobalamin 0.5 mg t.i.d. for 24 weeks. At the
end of the treatment period, patients from both groups
showed significant reductions in both the neuropathy
symptom score and neuropathy disability score, with no
meaningful difference between the two groups.
Neurophysiological parameters were also improved in
both groups.
Acetyl-L-carnitine in antiretroviral toxic
neuropathy
One Class II RCT was conducted in patients with antire-
troviral toxic neuropathy.27 This is a double-blind placebo-
controlled study testing the safety and efficacy of ALC
compared to placebo in the treatment of pain in HIV-
positive patients with distal symmetric polyneuropathy
related to antiretroviral drugs.28 Ninety patients were
included in the trial, randomized to receive ALC
1,000 mg/day (500 mg intramuscularly twice daily) during
the 14-day double-blind phase. During the 42 days of
open-treatment follow-up phase, ALC was administered
in the form of 1,000 mg oral sachets twice a day. The
treatment efficacy on pain was evaluated using VAS, Total
Symptom Score (TSS), Clinical Global Impression of
Change, McGill Pain Questionnaire (MPQ), and the need
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for rescue analgesics. For the efficacy-evaluable popula-
tion, the group of patients treated with ALC showed a
significantly greater reduction in pain, compared to the
placebo group. During the open-label phase, VAS, TSS
and MPQ revealed a pain relief. Intramuscular and oral
treatments were generally safe and well tolerated; the viral
load, CD4/CD8 ratio and CD4 and CD8 counts remained
stable, thus revealing that ALC treatment was not asso-
ciated with any progression of HIV infection.
Several open-label studies including patients with anti-
retroviral toxic neuropathy have been carried out. One
study, involving 21 HIV-positive patients with established
neuropathy, assessed the effect of oral ALC (1,500 mg
twice daily) on dermal and intraepidermal innervation.29
After a 6-month treatment, the mean immunostaining area
for small sensory fiber increased in all fiber types, includ-
ing sympathetic fibers: the epidermal, dermal and sweat
gland innervation reached 92%, 80% and 69%, respec-
tively compared with the control group. Neuropathic pain
grade improved in 76% of patients, whereas it remained
unchanged in 19%. No association of ALC treatment with
any progression of HIV infection was observed. An open-
label, single-arm pilot study involving 21 patients, evalu-
ated the effect of 3,000 mg ALC daily on the intra-epider-
mal nerve fiber (IENF) density and mitochondrial DNA
(mtDNA) copies/cell.30 Whereas IENF density and
mtDNA copies/cell did not change after therapy, improve-
ments in neuropathic pain, paresthesias, and symptoms of
numbness were observed. An open-label study, involving
20 subjects with painful antiretroviral toxic neuropathy,
tested the efficacy of oral ALC at a dose of 2,000 mg/
day for a 4-week period.31 Mean pain intensity score,
evaluated using the modified short-form MPQ, was sig-
nificantly lowered during the study, whereas electrophy-
siological parameters did not show significant changes.
Other two open label studies, totaling 26 patients, revealed
a positive effect of ALC in reducing neuropathic pain
intensity.32,33
Acetyl-L-carnitine in chemotherapy
induced neuropathy
Clinical studies tested the neuroprotective effect of ALC in
chemotherapy-induced neuropathy but no data about neu-
ropathic pain reduction are available.
A prospective, double-blind, Class II RCT study total-
ing 239 patients with chemotherapy-induced peripheral
neuropathy tested the effect of oral administration ofTa
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ALC 3 g/day.34 This study considered as primary endpoint
the improvement of peripheral neuropathy by at least one
grade according to the National Cancer Institute Common
Toxicity Criteria version 3.0. Patients conditions were
assessed at week 4, 8 and 12 after enrollment. At week
8, 51.6% patients treated with ALC met the primary end-
point, compared with 23.1% of patients in the placebo
group. Secondary endpoints, such as sural nerve conduc-
tion velocity and the Karnofsky physical score showed
also a significant improvement in patients treated with
ALC, compared to the placebo group. No significant dif-
ference in the incidence of adverse events between the two
groups was observed.
Two open label studies tested the effect of ALC in
patients with neuropathy induced by paclitaxel and
cisplatin.35,36 Maestri and colleagues tested the effect of
ALC 1 g/day i.v. infusion over 1–2 h for at least 10 days in
27 patients; the peripheral neuropathy improved in 73% of
them. Bianchi and colleagues tested oral ALC (1 g t.i.d.)
for 8 weeks in 25 patients. The total neuropathy score,
including neurophysiological measures, improved in 92%
of them.
Three studies totaling 578 patients with cancer inves-
tigated the effect of ALC in preventing chemotherapy-
induced neuropathy, but no positive effect was detected.-
37–39
Acetyl-L-carnitine in patients with carpal
tunnel syndrome
Neuropathic pain is a common symptom in patients with
Carpal tunnel syndrome (CTS).40
A recent multicenter, examiner-blinded, clinical and
neurophysiological study assessed the efficacy of ALC
on neuroprotection, pain, and function in CTS.15 The
study included eighty-two patients with CTS of mild-to-
moderate severity. Patients conditions were assessed at
baseline and after 10, 60 and 120 days of treatment.
After a first 10-day period of intramuscular injections
ALC 500 mg b.i.d., patients received an oral treatment
consisting of one tablet of ALC 500 mg b.i.d., for
110 days. Each patient underwent a median nerve conduc-
tion study, the Boston Carpal Tunnel Questionnaire
(BCTQ) and the Neuropathic Pain Symptom Inventory
(NPSI). The BCTQ score was significantly improved,
especially in the symptom component. Squeezing, pressure
pain and pain evoked by pressure, were significantly low-
ered. These symptom improvements were detected after
the first 10 days of intramuscular treatment and persisted
throughout the 4-month treatment period. All sensory neu-
rophysiological measures significantly improved.
Meta-analysis of RCTs in diabetic and
HIV-related painful peripheral neuropathy
Four RCTs tested the effect of ALC in comparison with
placebo in patients with diabetic and antiretroviral toxic
neuropathy (Table 2). A random-effects model was used
for the analysis, given that the heterogeneity indexes
approached the statistical significance (τ2=88.58; χ2=8.06,
df=3, P=0.045; I2=62.8%). Compared to placebo, ALC
produced a pain reduction equal to 20.2% (95% CI: 8.3–
32.1%, P<0.0001) with respect to baseline. The forest plot,
displaying the results from individual studies as well as the
pooled effect with the relevant CI, is reported in Figure 2.
A subgroup analysis considering only the three studies
conducted in diabetic peripheral neuropathy was carried
out (Table 3). Even in this case, a random-effects model
was used (τ2=50.28; χ2=3.40, df=2, P=0.18; I2=41.2%).
With respect to baseline, the mean difference in pain
Pooled meta-analysis
Youle, 2007
Sima UCE, 2005
Sima UCE, 2005
De Grandis, 2002
–40 –30 –20 –10 0 10
Mean VAS variation (% w.r.t. baseline)
Figure 2 Forest plot of randomized controlled trials in the meta-analysis. Each value is expressed as mean difference (95% CI).
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reduction was equal to 24.6% (95% CI: 12.4%÷36.8%,
P<0.0001): these results match those reported by Li and
colleagues.14 The test addressing the differences between
the diabetic subgroup versus the HIV therapy-related study
revealed a meaningful heterogeneity (χ2=2.31, df=1,
P=0.13; I2=56.7%). Table 4 provides details on the risk
of bias assessment for each study. In general, reporting of
randomization methods and treatment allocation was
clearly stated in De Grandis and colleagues25 and in
Youle and colleagues28 whereas it was uncertain in Sima
and colleagues24 therefore associated with an uncertain
bias risk. Allocation concealment and blinding were
addressed in De Grandis and colleagues.25
Effects of ALC on nerve function
Controlled trials in large cohorts of patients with periph-
eral neuropathy of different etiologies tested the effect of
ALC on neurophysiological measures. In the double-blind
RCT of De Grandis and colleagues, involving 333 patients
with diabetic neuropathy, the mean nerve conduction velo-
city and amplitude significantly improved, in comparison
with placebo.25 In two randomized placebo-controlled
trials, totaling 1257 patients with diabetic neuropathy,
Sima and colleagues failed to find any significant electro-
physiological change in patients treated with 500 or
1,000 mg ALC, although a significant improvement in
the vibration perception threshold was reported.24 A
short-term, double-blind clinical study involving 426
patients with peripheral neuropathy of different etiologies,
showed statistically meaningful differences between the
ALC and placebo groups in terms of mean conduction
velocity improvement.41
A double-blind, randomized placebo-controlled study,
totaling 239 patients with chemotherapy-induced periph-
eral neuropathy, reported a meaningful increase of sural
nerve conduction velocity after ALC treatment.34
The neuroprotective effect of ALC in CTS was tested
in a multicenter, examiner-blinded, clinical and neurophy-
siological study totaling 82 patients. The primary outcome,
ie the sensory conduction velocity of the median nerve,
significantly improved after 4 months of treatment. Such
an improvement, detected after the first 60 days of treat-
ment, persisted throughout the treatment period, lasting
4 months. The sensory action potentials amplitude of the
median nerve increased from baseline to the end of the
study.15 In addition, both the symptom and functional
BCTQ scores significantly decreased.Ta
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Discussion
According to preclinical and clinical studies, ALC can
be considered both an etiological and symptomatic treat-
ment in patients with peripheral neuropathy, with a good
safety profile. ALC operates via several mechanisms,
inducing regeneration of injured nerve fibers, reducing
oxidative stress, promoting DNA synthesis in mitochon-
dria, and increasing NGF concentrations in neurons,
thus promoting neurite extension.3,7 A lack of carnitine
reduces energy synthesis by impairing fatty acid degra-
dation: this condition was reported in association with
diabetes and its complications.42,43 A cross-sectional
study in HIV patients treated with antiretroviral nucleo-
side analogs showed that in patients with axonal periph-
eral neuropathy ALC levels are significantly lower
compared to the control groups.44 Under specific condi-
tions, the demand for ALC may exceed the capacity to
synthesize this essential micronutrient.25 In addition,
ALC production may be impaired by genetic defects.
ALC showed analgesic properties, by relieving acute
and in chronic pain. Several clinical studies reported an
improvement in symptoms after ALC supplementation
in patients with peripheral neuropathy of different
etiologies.31,36,45 Several works, describing different
neuropathic pain models, confirmed the antinociceptive
effect of ALC. Such an effect results from different
mechanisms, including the activation of muscarinic cho-
linergic receptors, and the increased expression of
mGlu2 receptors in dorsal root ganglia neurons, by
means of an acetylation mechanism involving transcrip-
tion factors of the nuclear factor (NF)-kappaB
family.17,20 Noteworthy, the analgesic effect of ALC
exceeds by several days or weeks the end of treatment,
in models of chronic inflammatory and neuropathic pain.
This enforces the role of ALC as an analgesic drug and
supports the role of the epigenetic mechanisms in the
treatment of chronic pain.17
For the first, a systematic review of literature was
carried out, by providing a classification for the available
clinical trials, and the level of evidence for: diabetic neu-
ropathy, antiretroviral toxic neuropathy, chemotherapy
induced neuropathy and CTS.
According to the AAN classification, ALC is probably
effective in diabetic neuropathy. The presence of a single
Class II trial for each type confirm the possible effect of
ALC in both antiretroviral toxic neuropathy and in che-
motherapy induced neuropathy. No RCT was performed in
patients with CTS, but results obtained from a recent
multicenter, examiner-blinded, clinical and neurophysiolo-
gical study are promising.
Pooled results from the present meta-analysis, includ-
ing four RCTs in patients with diabetic and antiretroviral
toxic neuropathy, showed the efficacy of ALC compared
to placebo in reducing pain intensity. In the subgroup
analysis, patients with diabetic neuropathy reported greater
pain reduction compared to patients with HIV-related per-
ipheral neuropathy. Moderate heterogeneity, as measured
by the I2 index, was observed among the RCTs; no sig-
nificant heterogeneity was found in studies belonging to
the diabetes subgroup. This meta-analysis has some lim-
itations: only four RCTs with small or moderate sized
were included. The length of follow-up was relatively
short- and the long-term impact of ALC is unknown.
According to a recent systematic review and meta-
analysis the effect of ALC on VAS in patients with painful
neuropathy was similar for different administration routes
(intramuscular and oral sequential administration and oral
administration only).14
A recent multicenter, examiner-blinded, clinical and neu-
rophysiological study assessed the effects of ALC in patients
with mild to moderate CTS.15 By means of its neuroprotective
action and central anti-nociceptive properties, ALC provided a
significant pain reduction, asmeasured byNPSI questionnaire.
More in detail, squeezing pain, pressure pain and pain evoked
Table 4 Bias assessment
Methodological items De Grandis, 2002 Sima UC, 2005 Sima UCE, 2005 Youle, 2007
Random sequence generation Low risk Uncertain risk Uncertain risk Low risk
Allocation concealment Low risk Uncertain risk Uncertain risk Uncertain risk
Blinding of participants and personnel Low risk Uncertain risk Uncertain risk Uncertain risk
Blinding of outcome assessment Low risk Uncertain risk Uncertain risk Uncertain risk
Incomplete outcome data Low risk Low risk Low risk Low risk
Selective reporting Uncertain Uncertain risk Uncertain risk Uncertain risk
Other bias Low risk Low risk Low risk Low risk
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by pressure, were significantly lowered. Pain reduction was
detected after the first 10 days of intramuscular treatment. The
intramuscular administration could allow reaching high con-
centrations of ALC in the central nervous system, an essential
condition for activating and boosting the epigenetic mechan-
isms underlying the analgesic action of the drug. However,
once the epigenetic mechanism has been triggered, no more
differences between intramuscular and oral administration are
expected.
Future RCT trials in patients with painful peripheral
neuropathy of different etiology are needed.
Conclusion
ALC is an effective and safe treatment in painful periph-
eral neuropathy, especially in diabetic patients. Future
studies aiming to assess the duration of the therapeutic
efficacy and the optimal dose in larger populations, possi-
bly with longer follow-up periods, are required.
The pain reduction induced by ALC may be mediated by
both a neuroprotective and a central anti-nociceptive mechan-
ism. Future studies should investigate the role of the two
mechanisms.
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